Cargando…

Efficiency of Original versus Generic Intravenous Iron Formulations in Patients on Haemodialysis

AIMS: The appropriate use of intravenous (IV) iron is essential to minimise the requirements for erythropoiesis-stimulating agents (ESAs). The clinical efficacy of generic IV iron compared to the original formulation is controversial. We evaluated the changes that were induced after switching from a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Agüera, Maria Luisa, Martin-Malo, Alejandro, Alvarez-Lara, Maria Antonia, Garcia-Montemayor, Victoria Eugenia, Canton, Petra, Soriano, Sagrario, Aljama, Pedro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4555833/ https://www.ncbi.nlm.nih.gov/pubmed/26322790 http://dx.doi.org/10.1371/journal.pone.0135967

Ejemplares similares

Phosphate control in reducing FGF23 levels in hemodialysis patients
por: Rodelo-Haad, Cristian, et al.
Publicado: (2018)

Predicting mortality in hemodialysis patients using machine learning analysis
por: Garcia-Montemayor, Victoria, et al.
Publicado: (2020)

High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis
por: Petrie, Mark C, et al.
Publicado: (2021)

Role of endothelial microvesicles released by p-cresol on endothelial dysfunction
por: Guerrero, Fatima, et al.
Publicado: (2020)

Ferrous iron content of intravenous iron formulations
por: Gupta, Ajay, et al.
Publicado: (2016)

Iron infusion and newer intravenous iron formulations
por: Aung, Tim, et al.
Publicado: (2021)

Passage Number-Induced Replicative Senescence Modulates the Endothelial Cell Response to Protein-Bound Uremic Toxins
por: Guerrero, Fatima, et al.
Publicado: (2021)

Inflammation, Senescence and MicroRNAs in Chronic Kidney Disease
por: Carmona, Andres, et al.
Publicado: (2020)

Intravenous iron and erythropoiesis‐stimulating agents in haemodialysis: A systematic review and meta‐analysis
por: Roger, Simon D, et al.
Publicado: (2017)

Hemodiafiltration with ultrafiltrate regeneration reduces free light chains without albumin loss in multiple myeloma patients
por: Pendón-Ruiz de Mier, M. Victoria, et al.
Publicado: (2020)

Administration of Intravenous Iron Formulations Induces Complement Activation in-vivo
por: Faria, Bernardo, et al.
Publicado: (2019)

INFERR-Iron infusion in haemodialysis study: INtravenous iron polymaltose for First Nations Australian patients with high FERRitin levels on haemodialysis—a protocol for a prospective open-label blinded endpoint randomised controlled trial
por: Majoni, Sandawana William, et al.
Publicado: (2021)

Comparative Evaluation of Nephrotoxicity and Management by Macrophages of Intravenous Pharmaceutical Iron Formulations
por: Connor, James R., et al.
Publicado: (2015)

Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial
por: Roberts, Matthew A., et al.
Publicado: (2016)

Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations
por: Pai, AB, et al.
Publicado: (2017)

Forty years on haemodialysis with the original arteriovenous fistula
por: Nicolai, Giulia Adriana, et al.
Publicado: (2012)

Pyrexia of unknown origin in a haemodialysis patient
por: Davenport, A.
Publicado: (2008)

Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics
por: Zuluaga, Andres F, et al.
Publicado: (2009)

Differences between intravenous iron products: focus on treatment of iron deficiency in chronic heart failure patients
por: Martin‐Malo, Alejandro, et al.
Publicado: (2019)

Safety and efficacy of generic drugs with respect to brand formulation
por: Gallelli, Luca, et al.
Publicado: (2013)

Evaluation of Physical Properties of Generic and Branded Travoprost Formulations
por: Wadhwani, Meenakshi, et al.
Publicado: (2016)

Chemoradiotherapy With Generic Cisplatin Formulations for Head and Neck Cancers
por: Shimada, Rie, et al.
Publicado: (2018)

Levothyroxine Formulations: Pharmacological and Clinical Implications of Generic Substitution
por: Benvenga, Salvatore, et al.
Publicado: (2019)

Pancreatic autoantibodies and CD14(+)CD16(+) monocytes subset are associated with the impairment of ß-cell function after simultaneous pancreas-kidney transplantation
por: Rodelo-Haad, Cristian, et al.
Publicado: (2019)

Colloidal Iron Oxide Formulation for Equine Hoof Disinfection
por: Isola, Maurizio, et al.
Publicado: (2021)

Cyclosporine: A Commentary on Brand versus Generic Formulation Exchange
por: Singh, A. K., et al.
Publicado: (2011)

Regulatory filing strategy for generic mesalazine modified release formulations
por: Gupta, Sandeep K.
Publicado: (2011)

Bioequivalence Evaluation in Healthy Volunteers: New Generic Formulations of Sitagliptin and Sitagliptin–Metformin Fixed-Dose Combination Compared with the Originator Products
por: Schnaars, Yvonne, et al.
Publicado: (2022)

Analysis of Adverse Events and Intravenous Iron Infusion Formulations in Adults With and Without Prior Infusion Reactions
por: Arastu, Asad H., et al.
Publicado: (2022)

Conversion of haemodialysis patients from iron sucrose to iron isomaltoside: a real-world experience
por: Jesus-Silva, Jorge A., et al.
Publicado: (2020)

Bioequivalence Studies of New Generic Formulations of Vildagliptin and Fixed-Drug Combination of Vildagliptin and Metformin Versus Respective Originator Products in Healthy Volunteers
por: Schnaars, Yvonne, et al.
Publicado: (2022)

Sampling times and genotyping concerns in bioequivalence evaluation of branded and generic formulations
por: Zhao, Xiao-Ying, et al.
Publicado: (2013)

In Vitro Toxicity Evaluation of New Generic Latanost(®) and Latacom(®) as an Ophthalmic Formulation
por: Ng, Jessica Sze Chia, et al.
Publicado: (2021)

Impact of Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibody C1q-Binding Ability on Kidney Allograft Outcome
por: Molina, Juan, et al.
Publicado: (2017)

Venous versus arterial iron administration in haemodialysis. Influence on erythrocytes antioxidant parameters
por: Dogaru, CB, et al.
Publicado: (2015)

Circulating Omentin-1 levels and altered iron balance in chronic haemodialysis patients
por: Bolignano, Davide, et al.
Publicado: (2021)

Impact of the COVID pandemic on vascular access creation for haemodialysis in 16 Spanish haemodialysis centres
por: Arenas Jimenez, María Dolores, et al.
Publicado: (2022)

Does China’s competitive generic substitution policy deliver equivalent clinical outcomes? A pilot study with two generic formulations of olanzepine
por: Zhang, Chao, et al.
Publicado: (2023)

Uremic Toxins Induce THP-1 Monocyte Endothelial Adhesion and Migration through Specific miRNA Expression
por: Carmona, Andres, et al.
Publicado: (2023)

The Efficacy and Safety Profile of Generic Intravenous Levetiracetam in a Real-World Setting
por: Ruangritkul, Preechaya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c9e9h9lsgkoormaif639v5taoa